-64%

est. 2Y upside i

FinTechSeries A

Making private healthcare in India accessible and affordable

Rank

#870

Sector

Healthcare Fintech

Est. Liquidity

~4Y

Data Quality

Data: High

SaveIN presents a moderate upside opportunity for a job seeker, driven by its impressive revenue growth (250% YoY for FY25, targeting 300% for FY26) and strong unit economics, aiming for organizational break-even in FY25.

Last updated: March 10, 2026

Bull (35%)+300%

SaveIN successfully leverages its extensive healthcare provider network and the 'welUp' platform to capture significant market share in both point-of-sale financing and enterprise wellness. Achieving its 3x revenue growth target for FY26 and sustaining high growth, revenue reaches $20M-$25M by 2028, justifying a $260M+ valuation at a 10-12x multiple, driven by strong unit economics and market leadership in its niche.

Base (30%)+50%

SaveIN continues to grow its core healthcare point-of-sale financing business, reaching its FY26 revenue target of $5.55M and expanding moderately. While maintaining unit economics profitability, competitive pressures and the high regulatory environment temper growth, leading to $10M-$12M in revenue by 2028 and a valuation of approximately $97.5M at an 8-9x multiple.

Bear (35%)-75%

Dominant incumbents or well-funded fintech competitors launch aggressive point-of-care financing solutions, eroding SaveIN's market share and pricing power. Regulatory changes or increased capital intensity strain operations, leading to stalled growth at $5M-$7M revenue and a down round or low acquisition at $16.25M, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $12M in liquidation preferences. In an exit at or below $12M, common stock holders would receive nothing. For an exit between $12M and $65M, investors are paid first, significantly reducing common stock value.

Dilution Risk

high

As a Series A company, SaveIN will likely require 1-2 more significant funding rounds, which will lead to further dilution of existing equity holders.

Secondary Liquidity

none

As an early-stage company, there are no active secondary markets or tender offers for SaveIN equity.

Questions to Ask at the Interview

Strategic questions based on SaveIN's data — designed to show you've done your homework.

  • 1

    “SaveIN has achieved unit economics profitability and aims for organizational break-even in FY25, alongside targeting 3x revenue growth in FY26. How do you plan to balance aggressive growth with maintaining or improving profitability in the highly competitive Indian fintech and healthcare market?”

  • 2

    “Your competitive moat is described as moderate, leveraging network effects and switching costs, while facing a medium incumbent threat from large insurance companies and traditional lenders. How does SaveIN plan to further strengthen its competitive position and defend against potential deeper incursions from these established players, particularly as they might eye the point-of-care financing segment?”

  • 3

    “Given the Series A funding and the typical venture lifecycle, what is the company's anticipated timeline and strategy for future funding rounds and ultimately, a liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -64% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.